Promising Prospects for 4D Molecular Therapeutics: Anticipated Growth in wAMD Treatment and Market Valuation

In a report released yesterday, Daniel Giraldo from Bank of America Securities maintained a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of $42.00.

Daniel Giraldo’s rating is based on several promising factors surrounding 4D Molecular Therapeutics. The company is poised for a significant update regarding its 4D-150 treatment for wet age-related macular degeneration (wAMD), with experts anticipating that about 50% of patients could remain injection-free for 52 weeks. This expectation follows a previous update showing 73% of patients injection-free at 32 weeks, indicating a potential trend toward durable responses. Additionally, reducing the overall treatment burden to just 1-2 injections per year is seen as a meaningful clinical benefit, potentially expanding the treatment’s use to 10-20% of wAMD patients.
Moreover, the safety profile of 4D-150 remains strong, with no concerns raised so far, which is crucial for long-term success. Experts emphasize the importance of maintaining this clean safety profile, especially after the steroid tapering regimen. The data thus far suggests a large commercial opportunity, with the stock currently undervalued. Giraldo’s confidence is further supported by a model projecting $1.7 billion in risk-adjusted peak sales for 4D-150, solidifying the Buy rating with a price objective of $42.

In another report released on January 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $36.00 price target.

FDMT’s price has also changed dramatically for the past six months – from $15.130 to $6.140, which is a -59.42% drop .